BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Other Events

Item 8.01. Other Events.

On February 27, 2017, BioCryst Pharmaceuticals, Inc. (the
Company) announced positive results from an interim analysis of
its Phase 2 APeX-1 trial in hereditary angioedema (HAE). APeX-1
is a dose ranging trial designed to evaluate the efficacy,
safety, tolerability, pharmacokinetics and pharmacodynamics of
orally administered once daily BCX7353 for 28 days, as a
preventative treatment to reduce the frequency of attacks in HAE
patients.

On February 27, 2017, the Company issued a news release
announcing the events described in this Item 8.01. A copy of the
news release is filed as Exhibit 99.1 hereto and is incorporated
herein by reference.

Forward-Looking Statements

This Current Report contains forward-looking statements,
including statements regarding future results, performance or
achievements. These statements involve known and unknown risks,
uncertainties and other factors which may cause BioCrysts actual
results, performance or achievements to be materially different
from any future results, performances or achievements expressed
or implied by the forward-looking statements. These statements
reflect our current views with respect to future events and are
based on assumptions and are subject to risks and uncertainties.
Given these uncertainties, you should not place undue reliance on
these forward-looking statements. Some of the factors that could
affect the forward-looking statements contained herein include:
developing any HAE drug candidate may take longer or may be more
expensive than planned; ongoing and future preclinical and
clinical development of HAE second generation drug candidates
(including APeX-1) may not have positive results; that BioCryst
may not be able to enroll the required number of subjects in
planned clinical trials of product candidates; that the Company
may not advance human clinical trials with product candidates as
expected; that the FDA may require additional studies beyond the
studies planned for product candidates, or may not provide
regulatory clearances which may result in delay of planned
clinical trials, or may impose a clinical hold with respect to
such product candidate, or withhold market approval for product
candidates; that BioCryst may not receive additional government
funding to further support the development of galidesivir; that
galidesivir development may not be successful; that BARDA and/or
NIAID may further condition, reduce or eliminate future funding;
that revenue from peramivir is unpredictable and
commercialization of peramivir may never result in significant
revenue for the Company; that the Company may not be able to
continue development of ongoing and future development programs;
that such development programs may never result in future
products; that actual financial results may not be consistent
with expectations, including that 2017 operating expenses and
cash usage may not be within managements expected ranges. Please
refer to the documents BioCryst files periodically with the
Securities and Exchange Commission, specifically BioCrysts most
recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, all of which identify
important factors that could cause the actual results to differ
materially from those contained in BioCrysts projections and
forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session down -0.11 at 5.49 with 1,367,156 shares trading hands.